Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-23T00:04:48.292Z Has data issue: false hasContentIssue false

14 - Vaccine research

Published online by Cambridge University Press:  27 August 2009

Mark A. Feitelson
Affiliation:
Thomas Jefferson University, Philadelphia
Get access

Summary

The development of a protective HCV vaccine has been among the most diffcult challenges since the discovery of the virus for a number of reasons. First, despite the consistent efforts of many laboratories, there is still no permissive system that consistently replicates HCV at high enough levels to evaluate antibodies that may be neutralizing (Table 11.1 and Ch. 11). Second, with the exception of the chimpanzee, which is expensive, endangered, and diffcult to work with, there are no convenient animal models that are susceptible to HCV and that could be used for candidate vaccine challenge studies (Section 1.2). Third, the genotype, subtype and quasispecies nature of HCV (Weiner et al., 1992; Bukh et al., 1997; Simmonds et al., 1993, 1997) (Section 3.2) may require the construction of polyvalent vaccines that would protect against a large number of closely related epitopes. The fact that the genetic heterogeneity of the virus can change rapidly in an infected individual (Ogata et al., 1991), and that antiviral immunity may select for neutralization escape mutants (within HVR1) (Martell et al., 1992; Weiner et al., 1992; Shimizu et al., 1994) as well as CTL escape mutants (Weiner et al., 1995), may limit the effectiveness and utility of any vaccine. Fourth, it is not clear whether the envelope polypeptides contain all of the antigenic determinants required for effective neutralization (Chien et al., 1993).

Type
Chapter
Information
Hepatitis C Virus
From Laboratory to Clinic
, pp. 123 - 126
Publisher: Cambridge University Press
Print publication year: 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Vaccine research
  • Mark A. Feitelson, Thomas Jefferson University, Philadelphia
  • Book: Hepatitis C Virus
  • Online publication: 27 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545320.016
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Vaccine research
  • Mark A. Feitelson, Thomas Jefferson University, Philadelphia
  • Book: Hepatitis C Virus
  • Online publication: 27 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545320.016
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Vaccine research
  • Mark A. Feitelson, Thomas Jefferson University, Philadelphia
  • Book: Hepatitis C Virus
  • Online publication: 27 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545320.016
Available formats
×